More work is needed to understand the burden of comorbidities in people with multiple sclerosis (MS).
Objective:
To assess prevalence of 30 comorbidities and impacts of comorbidities on employment outcomes in a working-aged MS cohort.
Methods:
Participants were from the Australian MS Longitudinal Study (n = 929). Information on specific comorbidity was obtained (whether or not each was present, doctor-diagnosed, limited their activities and being treated).
Results:
Comorbidities most frequently reported to limit activities were osteoarthritis (51%), migraines (40%), anxiety (33%), depression (29%) and allergies (18%). Mean MS-related work productivity loss in past 4 weeks was 1.3 days for those without comorbidities and 2.5 days for those with any comorbidity. The annual population costs of work productivity loss were highest for people with depression, allergies, anxiety, migraines and osteoarthritis. Higher number of comorbidities was associated with more work productivity loss and a higher likelihood of not working. These associations were substantially reduced after adjustment for MS symptom severity.
Conclusions:
Comorbidities substantially impact employment outcomes and these effects were mainly mediated through MS symptom severity. This suggests that optimal and simultaneous management of comorbidities may be a viable strategy to reduce MS symptom severity, which in turn could improve employment outcomes.
MarrieRACohenJStuveO, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler2015; 21(3): 263–281.
2.
MarrieRAPattenSBTremlettH, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology2016; 86(14): 1279–1286.
3.
MarrieRA.Comorbidity in multiple sclerosis: Implications for patient care. Nat Rev Neurol2017; 13(6): 375–382.
4.
TinghogPBjorkenstamCCarstensenJ, et al. Co-morbidities increase the risk of disability pension among MS patients: A population-based nationwide cohort study. BMC Neurol2014; 14: 117.
5.
MarrieRAFiskJDTremlettH, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology2015; 85(22): 1972–1979.
6.
TetteyPSiejkaDSimpsonSJr, et al. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology2016; 46(2): 106–113.
7.
MarrieRAHorwitzRCutterG, et al. The burden of mental comorbidity in multiple sclerosis: Frequent, underdiagnosed, and undertreated. Mult Scler2009; 15(3): 385–392.
8.
KangJHChenYHLinHC.Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur J Neurol2010; 17(9): 1215–1219.
9.
BrennerPAlexandersonKBjorkenstamC, et al. Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients: A population-based register study. PLoS ONE2014; 9(8): e104165.
10.
ChenJTaylorBPalmerAJ, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult Scler J2018; 25: 994–1004.
11.
FiestKMFiskJDPattenSB, et al. Fatigue and comorbidities in multiple sclerosis. Int J MS Care2016; 18(2): 96–104.
12.
FiestKFiskJPattenS, et al. Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Mult Scler Relat Disord2015; 4(5): 470–476.
13.
FinlaysonMPreissnerKChoC.Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis: An exploratory investigation. Int J MS Care2013; 15(1): 21–26.
14.
TaylorBVPalmerASimpsonSJr, et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler2013; 19(12): 1627–1631.
15.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
16.
ReillyMCZbrozekASDukesEM.The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics1993; 4(5): 353–365.
17.
ReillyMCGoochKLWongRL, et al. Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in ankylosing spondylitis. Rheumatology2010; 49(4): 812–819.
18.
WahlqvistPCarlssonJStalhammarNO, et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) – Results from a cross-sectional study. Value Health2002; 5(2): 106–113.
19.
ZhangWBansbackNBoonenA, et al. Validity of the work productivity and activity impairment questionnaire – General health version in patients with rheumatoid arthritis. Arthritis Res Ther2010; 12(5): R177.
20.
SandersonKTilseENicholsonJ, et al. Which presenteeism measures are more sensitive to depression and anxiety. J Affect Disord2007; 101(1–3): 65–74.
21.
LeggettSvan der Zee-NeuenABoonenA, et al. Content validity of global measures for at-work productivity in patients with rheumatic diseases: An international qualitative study. Rheumatology (Oxford)2016; 55(8): 1364–1373.
LearmonthYCMotlRWSandroffBM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol2013; 13: 37.
24.
HoholMOravEWeinerHL.Disease steps in multiple sclerosis: A simple approach to evaluate disease progression. Neurology1995; 45(2): 251–255.
25.
BarrosAJHirakataVN.Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol2003; 3: 21.
26.
BurkeWJ.Fitting and interpreting Cragg’s tobit alternative using Stata. Stata J2009; 9: 584–592.
27.
RaissiABullochAGFiestKM, et al. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care2015; 17(6): 292–300.
28.
BerriganLIFiskJDPattenSB, et al. Health-related quality of life in multiple sclerosis direct and indirect effects of comorbidity. Neurology2016; 86(15): 1417–1424.
29.
FeinsteinAMagalhaesSRichardJF, et al. The link between multiple sclerosis and depression. Nat Rev Neurol2014; 10: 507–517.
30.
The Consortium of Multiple Sclerosis Centers. Comorbidities in multiple sclerosis: A clinical resource guide. https://mscomorbidities.com/(2018, accessed 17 September 2018).
FeysPGiovannoniGDijsselbloemN, et al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler2016; 22(2 Suppl.): 34–46.
33.
National Clinical Guideline Centre and National Institute for Health and Care Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence, 2014.
34.
DegenhardtARamagopalanSVScalfariA, et al. Clinical prognostic factors in multiple sclerosis: A natural history review. Nat Rev Neurol2009; 5(12): 672–682.
35.
MarrieRAYuBNLeungS, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: Validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler2012; 18(9): 1310–1319.
36.
MarrieRRudickRHorwitzR, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology2010; 74(13): 1041–1047.
